CDK4 and cancer: However, recent successes in developing KRAS inhibitors represent a significant milestone in cancer research, potentially revolutionizing treatment for KRAS-driven malignancies such as pancreatic, non-small cell lung, and colon cancers.697,698 Co-targeting CDK4/6 and KRAS in these settings holds promise for improving clinical outcomes.